As I have written many times before postpartum hemorrhage (PPH) or excessive uterine bleeding after childbirth is the leading cause of maternal mortality in low-and-middle income countries. The recommended drug to prevent PPH according to the World Health Organization (WHO) is oxytocin. When administered in its recommended dose it causes little to no side effects. Oxytocin, the WHO’s current gold standard therapy, however, must be refrigerated and administered by skilled health workers posing two obstacles to its wider use in low resource, tropical settings.
Some countries have approved misoprostol, an oral drug, to prevent PPH, but there are several concerns that its use can be misappropriated for abortions instead of used solely for PPH. The World Health Organization has listed misoprostol as an alternative to oxytocin if it is not available.
Now, another PPH preventative drug, carbetocin, has been added to the latest updated 2019 WHO Essential Medicines List. The announcement was made last week. Unlike oxytocin, even at high temperatures carbetocin remains effective. The recommendation is that carbetocin can be used when oxytocin is not available or if its quality is uncertain. Additionally, the cost must be comparable to oxytocin.
Continue reading NEW: Drug That Prevents PostPartum Hemorrhage Added To WHO Essential Medicines List
When people think about new inventions, 95% of them immediately begin thinking about tech inventions, but what about medical inventions that save lives?
Merck recently launched a video that asked Americans what invention they are waiting for. Take a look.
Did you know 68% of Americans cannot name a single scientist working to invent medicine?
Merck has been working for over a century on medicines and vaccines that save lives. Visit their site on Inventing for Life where you can see a timeline of Merck’s work as well as meet some of its scientists, and see some of its impact on the world’s most challenging diseases.
I’m happy to share this video today as I know how important their work is on maternal health with Merck for Mothers.
Earlier this month I wrote about Uganda’s move to use misoprostol for women who experience postpartum hemorrhage (PPH) during childbirth or immediately after delivery. PPH is the leading cause of maternal mortality for women around the world. 800 women die every day from complications during pregnancy and delivery; that is two mothers a minute.
Misoprostol, it has been found, is effective because it will stop a woman’s bleeding, can be taken in pill form and can be stored at hotter temperatures. Oxytocin, which is the gold standard for stopping PPH must be stored in cold temperatures to be effective. However, in low-resource settings electricity can be touch and go or altogether nonexistent.
Last year Merck announced that they have partnered with the World Health Organization as well as Ferring Pharmaceuticals to test the efficacy in clinical trials of using carbetocin, another medication that can stop PPH, but can be stored in hot and tropical environments.
The clinical trials began this year in 12 countries that included 29,000 women. Through its Merck for Mothers initiative, Merck has partnered with organizations in the United States and abroad to reduce maternal mortality around the world.
Continue reading Merck and WHO Partner to Curb Postpartum Hemorrhage Deaths